---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-018522"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2023-02-10T23:59:59+00:00"
generated_at: "2026-06-19T17:56:09.495869+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Rezolute Q2 FY2023 net loss $13.6M; cash $146.7M; Phase 2 DME study initiated

## Summary
- Net loss $13.6M for Q2 FY2023 ended Dec 31, 2022 vs $12.6M same period prior year.
- Cash and cash equivalents $146.7M as of Dec 31, 2022.
- R&D expenses $10.9M, G&A expenses $3.4M, both up on higher compensation and headcount.
- Initiated Phase 2 proof-of-concept study for RZ402 in diabetic macular edema in Dec 2022.
- Anticipates initiating global Phase 3 study for RZ358 in congenital hyperinsulinism mid-2023.

## SEC filing metadata
- accession: 0001104659-23-018522
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2023-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465923018522/0001104659-23-018522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465923018522/tm236021d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-018522
- JSON: https://secwatch.observer/filing/0001104659-23-018522.json
- Plain text: https://secwatch.observer/filing/0001104659-23-018522.txt

## Key facts
- Earnings Releases
  Rezolute, Inc. reported financial results for second quarter of fiscal 2023 ended December 31, 2022.
  - Period: second quarter of fiscal 2023 ended December 31, 2022
  - Result: reported results
  source text: On February 10, 2023, Rezolute, Inc. issued a press release announcing its financial results for the second quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509261/000110465923018522/0001104659-23-018522-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.